HealthSignals coverage organized by therapeutic area: oncology, cardio-metabolic disease, rare and genetic diseases, neuroscience, immunology and infectious diseases across Latin America and the United States.
HealthSignals coverage organized by therapeutic area: oncology, cardio-metabolic disease, rare and genetic diseases, neuroscience, immunology and infectious diseases across Latin America and the United States.
The FDA on October 14 expanded Anktiva (nogapendekin alfa inbakicept-pmln) to adults with BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer, as ImmunityBio works through a March warning letter over its promotion …
Brazil’s federal health ministry began dispensing nine new cancer drugs through the public Sistema Único de Saúde (SUS) network this week, for more than 116,000 patients, and expects all 23 …
Mexico’s public mental health system is severely under-resourced even as nearly five million people in Mexico live with a mental health condition. The Instituto Mexicano del Seguro Social (IMSS) fields …
Brazil’s public health system (SUS) has added extended-release lithium on tolerability and adherence grounds, and the Dominican health-insurance regulator, the Superintendency of Health and Occupational Risks (SISALRIL), is studying wider …
The FDA approved GSK and Ionis’s bepirovirsen for a narrow group of adults with chronic hepatitis B; 19% of treated trial patients still had the virus controlled, with hepatitis B …
A committee of Conitec, Brazil’s health technology assessment body, provisionally recommended ViiV’s HIV-prevention injection at its proposed price of about R$6,660 a year, while Brazil offered Gilead roughly a third …
Chileans spend nearly US$100 million a year on weight-loss treatment, according to La Tercera, as seven generic semaglutide applications — including Laboratorio Chile’s Selfix — await regulatory review, putting Novo …
Telix Pharmaceuticals agrees to acquire ITM Isotope Technologies Munich for up to $2.35 billion, securing isotope supply and adding ITM-11, a Phase 3 neuroendocrine tumour candidate that received an FDA …
Cristália’s Phase 1 safety trial of polilaminina for acute spinal cord trauma was scheduled to begin 24 September 2026 after authorisation from Brazil’s health regulator, Anvisa, in January — with …
The FDA approved belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma after prior immunotherapy, adding a second approved indication for belzutifan in 2026 and expanding Merck …
You must be logged in to post a comment.